iX Biopharma inks agreement to distribute erectile dysfunction drug in China
Singapore
PHARMACEUTICAL company iX Biopharma, through its wholly-owned subsidiary, has struck an agreement with China Resources Pharmaceutical Commercial Group Co (CRPCG) for the licensing, supply and distribution of Wafesil, a sublingual sildenafil wafer for the treatment of male erectile dysfunction, in China.
In a bourse filing on Thursday, the company said that the new licensing agreement runs for an initial term of 10 years and will "allow both parties to tap on their collective strengths and capabilities to capture the vast opportunities in the China market".
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
Prudential shutters Hong Kong wealth unit Pulse
Singapore has to be realistic on global trends plaguing its stock market: DPM Wong
Google DeepMind unveils next generation of drug discovery AI model
AEM Holdings Q1 net profit tumbles 85% to S$2.4 million
World’s biggest tea buyer Lipton’s sale of last farms is a strategy shift
JPMorgan, Nomura limit Segantii exposure on Hong Kong case